SGEN:NSD-Seagen Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 185.75

Change

0.00 (0.00)%

Market Cap

USD 33.25B

Volume

1.36M

Average Target Price

USD 192.47 (+3.62%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.27B 18.98 14.64
MRNA Moderna, Inc

N/A

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD34.27B 36.37 33.83
RPRX Royalty Pharma plc

N/A

USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

N/A

USD31.01B N/A N/A
GMAB Genmab A/S

N/A

USD28.77B 26.59 3.08
BNTX BioNTech SE

N/A

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
INCY Incyte Corporation

N/A

USD19.83B 47.64 35.20

ETFs Containing SGEN

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.24B
AGES:LSE iShares Ageing Population.. 0.00 % 0.40 %

+3.00 (+0.55%)

USD0.27B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.40 %

+0.03 (+0.49%)

USD0.37B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.33%)

N/A
ITEK:LSE HAN-GINS Tech Megatrend E.. 0.00 % 0.75 %

-0.01 (-0.08%)

USD0.05B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

+0.02 (+0.14%)

USD1.87B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

+3.00 (+0.38%)

USD1.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.03 (+0.39%)

USD0.27B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.03 (+0.58%)

USD0.19B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.03 (+0.40%)

USD0.27B
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

+0.03 (+0.41%)

USD0.37B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD9.34M
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.24B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+0.33 (+0.79%)

USD0.03B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD0.16B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+0.33 (+0.44%)

USD0.51B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

N/A

USD10.37B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

+0.05 (+0.13%)

USD0.02B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

+0.03 (+0.29%)

USD1.87B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.06% 39% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.06% 39% F 55% F
Trailing 12 Months  
Capital Gain 70.41% 71% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.41% 71% C- 81% B-
Trailing 5 Years  
Capital Gain 397.32% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 397.32% 88% B+ 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 43.93% 76% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.93% 76% C 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 47.66% 55% F 26% F
Risk Adjusted Return 92.16% 99% A+ 91% A-
Market Capitalization 33.25B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 70.15 14% F 17% F
Price/Book Ratio 14.72 15% F 11% F
Price / Cash Flow Ratio -203.06 98% A+ 97% A+
EV/EBITDA 70.76 8% F 13% F
Management Effectiveness  
Return on Equity 23.40% 97% A+ 93% A
Return on Invested Capital -14.00% 86% B 31% F
Return on Assets 9.64% 98% A+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.69 37% F 29% F
Short Percent 7.18% 46% F 29% F
Beta 1.10 72% C- 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.